Previous studies have correlated survivin with an unfavorable clinical outcome in a variety of cancers, including colorectal cancer [8], breast cancer [9], lung cancer [10], esophageal cancer [11], brain tumor [13], soft tissue sarcoma [19], and hematologic malignancies [20]. This evidence concerns the gene BIRC5 and lung cancer.